NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY;OSAKA UNIVERSITY;MITSUBISHI TANABE PHARMA CORPORATION
发明人:
HASHIMOTO, MOTONORI,YAMASHITA, TOSHIHIDE
申请号：
RSP20191502
公开号：
RS59847B1
申请日:
2016.04.27
申请国别(地区):
RS
年份:
2020
代理人:
摘要：
The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.
